deferoxamine has been researched along with alpha-synuclein in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, M; Hsu, LJ; Masliah, E; Takeda, A; Takenouchi, T | 1 |
| Chetsawang, B; Ebadi, M; Govitrapong, P; Porter, J; Sangchot, P; Sharma, S | 1 |
| Caruana, M; Giese, A; Hillmer, A; Högen, T; Levin, J; Vassallo, N | 1 |
| Caldarola, S; Febbraro, F; Giorgi, M; Loreni, F; Romero-Ramos, M | 1 |
| Andersen, KJ; Febbraro, F; Romero-Ramos, M; Sanchez-Guajardo, V; Tentillier, N | 1 |
| Bader, B; Bötzel, K; Giese, A; Hillmer, AS; Högen, T; Kamp, F; Kretzschmar, HA; Levin, J; Schmidt, F | 1 |
| Bellier, JP; Guan, H; Mori, M; Nonaka, T; Takahata, S; Tooyama, I; Yanagisawa, D; Yang, H; Yang, M; Zhao, S | 1 |
7 other study(ies) available for deferoxamine and alpha-synuclein
| Article | Year |
|---|---|
Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease.
Topics: Acetylcysteine; alpha-Synuclein; Antioxidants; Brain; Cytochrome c Group; Deferoxamine; Humans; Hydrogen Peroxide; Immunohistochemistry; Lewy Body Disease; Nerve Tissue Proteins; Oxidative Stress; Recombinant Proteins; Synucleins | 1999 |
Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture.
Topics: Adenosine Triphosphate; alpha-Synuclein; Cell Survival; Deferoxamine; Ferric Compounds; Humans; Iron Chelating Agents; Lipid Peroxidation; Mitochondria; Nerve Tissue Proteins; Neuroblastoma; Oxidative Stress; Synucleins; Tumor Cells, Cultured | 2002 |
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.
Topics: Acetylcysteine; alpha-Synuclein; Antioxidants; Apigenin; Ascorbic Acid; Deferoxamine; Dose-Response Relationship, Drug; Flavanones; Flavonoids; Humans; Iron Chelating Agents; Microscopy, Confocal; Microscopy, Fluorescence; Molecular Structure; Mutation; Parkinson Disease; Phenols; Polyphenols; Protein Multimerization; Protein Structure, Quaternary; Recombinant Proteins; Spectrometry, Fluorescence; Structure-Activity Relationship | 2011 |
α-Synuclein expression is modulated at the translational level by iron.
Topics: alpha-Synuclein; Animals; Brain; Cells, Cultured; Deferoxamine; Ferric Compounds; HEK293 Cells; Humans; Iron; Kidney; Lewy Bodies; Parkinson Disease; Protein Biosynthesis; Quaternary Ammonium Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rodentia; Siderophores | 2012 |
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cell Line, Transformed; Corpus Striatum; Deferoxamine; Dextroamphetamine; Disease Models, Animal; Female; Forelimb; Gene Expression Regulation; Genetic Vectors; Humans; Motor Activity; Nerve Tissue Proteins; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Siderophores; Time Factors; Transfection; Tyrosine 3-Monooxygenase | 2013 |
Generation of ferric iron links oxidative stress to α-synuclein oligomer formation.
Topics: alpha-Synuclein; Ascorbic Acid; Deferoxamine; Dose-Response Relationship, Drug; Ferric Compounds; Humans; Hydrogen Peroxide; Microscopy, Confocal; Models, Biological; Oxidation-Reduction; Siderophores | 2011 |
Mitochondrial ferritin protects SH-SY5Y cells against H
Topics: alpha-Synuclein; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Line, Tumor; Deferoxamine; Down-Regulation; Ferritins; Ferrous Compounds; Green Fluorescent Proteins; Humans; Hydrogen Peroxide; Iron; L-Lactate Dehydrogenase; Mitochondria; Mitochondrial Proteins; Neuroblastoma; Oxidative Stress; Siderophores; Tretinoin; Tyrosine 3-Monooxygenase | 2017 |